Research Design: Retrospective, longitudinal cohort study. Medical record-abstracted, tumor registry-indicated treatments (gold standard) were compared with VDW-indicated treatments derived from health maintenance organization pharmacy, electronic medical record, and claim-based data systems.
M ost published research on the patterns of utilization and costs of cancer treatment have been limited to the linked Surveillance, Epidemiology and End Results (SEER)-Medicare data, National Comprehensive Cancer Network studies, or randomized clinical trials. [1] [2] [3] Although several studies have documented the reliability of SEER-Medicare data to capture chemotherapy administration, 4,5 SEER-Medicare data do not include details on treatment patterns and outcomes of cancer care for patients aged younger than 65 years or those receiving their care in health maintenance organizations (HMOs). Furthermore, detailed data on the use of antineoplastic agents are often captured only for a select group of patients who are not representative of the broader population of cancer patients. 5, 6 Generalizable data are needed to conduct comparative effectiveness research on treatment options commonly used in community-based oncology practices.
Such data are potentially available from HMOs that participate in the National Cancer Institute (NCI)-funded Cancer Research Network (CRN). [7] [8] [9] CRN HMOs compile and maintain data from internal, automated information systems in a distributed data network entitled the "Virtual Data Warehouse (VDW)." 10, 11 VDW encounter, claims, and electronic medical record (EMR) data have, in turn, been linked to validated tumor registry data derived from the abstraction of HMO enrollee charts using methods similar to (or in some cases equivalent to) SEER registries (http:// seer.cancer.gov/). Prior CRN research using "Virtual Tumor Registry" (VTR) data linked to VDW data has focused primarily on surveillance/screening [12] [13] [14] [15] epidemiologic, 16, 17 and survivorship studies. 18, 19 However, the VDW also captures HMO enrollees' use of antineoplastic agents and could therefore serve as a resource for population-based research on treatment patterns, diffusion of new therapies, and costs associated with the cancer treatment services provided in community settings for patients not currently represented by data derived from SEER-Medicare or randomized clinical trials.
One of the challenges of using HMO-automated data is lack of published validation studies assessing the quality of automated data against a consistent gold standard. Health information systems vary across HMOs (different hardware platforms and software vendors) and over time (upgrades to software and changes in vendors). Data derived from treatment, payment, and operations sources are not collected under research standards; data are entered by a multitude of clinicians and staff members with little redundant entry to assess reliability. Many uncontrolled factors underlying treatment, payment, and operations data create a need for formal evaluation of the validity and reliability of these data.
To validate the usefulness of CRN VDW data for the capture of chemotherapy and hormone therapy treatment among cancer patients aged 18 and older, we assessed the sensitivity, specificity, and positive predictive value (PPV) of indicators of first-course chemotherapy and hormone therapies found in the CRN VDW compared with a "gold standard" of chart-abstracted measures of first-course treatment contained in the tumor registries of 3 CRN HMOs.
METHODS

Study Design and Setting
This was a retrospective, longitudinal cohort study conducted within 3 nonprofit HMOs [the Colorado (Denver/ Boulder) and Northwest (Portland, OR/Vancouver, WA) regions of Kaiser Permanente, and Group Health Cooperative (Seattle, WA)]. Each HMO is a member of the CRN (NCI Cooperative Agreement No. U19 CA79689) and provides comprehensive health services to its members, primarily through closed panel delivery models by salaried physicians. In each of these HMOs, the majority of ambulatory cancer care is delivered in plan-owned facilities. This project was approved by the institutional review boards of the 3participating HMOs.
Data Sources
The primary data source for this analysis was the CRN's VDW. The VDW is a standardized data system in which CRN participating HMOs retain local control of their data, but a programmer at 1 site can write a program than can be run at all sites. 10, 11 The VTR contains standardized data derived from each CRN HMO's tumor registry. The VTR contains data consistent with the North American Association of Central Cancer Registries (NAACCR) standards 20 and includes information on each patient's cancer site, sequence, diagnosis date, American Joint Committee on Cancer stage, and receipt of primary chemotherapy, immunotherapy, hormone therapy, and surgical and radiotherapy, that are obtained from manual reviews of cancer patients' medical charts. Information from the VTR can be considered a gold standard for cancer treatment information because data contained within the VTR were collected by certified tumor registrars (CTRs) who review all elements of each patient's medical record, including pathology reports, imaging reports, infusion session summaries, surgical operation reports, physician orders (for chemotherapy and hormonal therapy), and clinician progress notes. For the 3 HMOs included in this study, 2 have internal registries staffed with full-time CTRs; neither are SEER sites, but both report NAACCR standard cases and fields to their respective State registries. The third HMO receives tumor registry data feeds, in NAACCR format, from the SEER Cancer Surveillance System. All diagnosis and treatment data provided to health plan enrollees were available for medical record review by the CTRs. Some variation was observed across the CRN sites and over time with respect to the capture of specific tumor registry variables. For example, not all CRN VTRs captured variables including date of first chemo or hormone therapy treatment for all years included in this study.
VDW diagnosis and procedure files include coded diagnoses and procedures associated with inpatient and outpatient encounters or events. These codes are based on International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes, Healthcare Common Procedure Coding System codes, or the 4th Edition of the Common Procedure Terminology codes (CPT-4). More than 90% of the VDW diagnosis and procedure data used in this analysis were derived from EMRs. These data capture the diagnoses and treatment associated with the chemotherapy events that take place predominately in health plan-owned ambulatory infusion centers. Claims data included in these analyses were associated with cancer treatments administered by contract providers including hospital based care. VDW pharmacy files capture national drug code (NDC)-based prescription drugs dispensed from both outpatient pharmacies and HMO-owned infusion centers. VDW files (VTR, procedure, diagnosis, and pharmacy) were linked by programmers at the individual CRN sites using individual medical record identifiers. These identifiers were then stripped from the analytic data sets before pooling data for final analyses. In this analysis, and consistent with Warren et al, 4 we focused on the ability of the VDW to capture definitive firstcourse chemotherapy and hormone therapy at 6 months after a patient's incident cancer diagnosis date from 4 VDW files: VTR, pharmacy, procedures, and diagnoses during the period of January 1, 2000 through December 31, 2008. Given the potential for the delay in first-course treatment, we repeated this analysis at 12 months after incident cancer diagnosis.
Study Sample
Cancer cases were identified in the VTR as individuals diagnosed with breast, colorectal, lung, or prostate cancer between January 1, 2000 and December 31, 2007, aged 18 or older at diagnosis, and eligible for care in 1 of the 3 HMOs for the year before and including the date of diagnosis.
Identification of Chemotherapy
Cancer therapy "look-up" tables were created by extracting codes from published research, 4,6,21 NCI websites, 22 ,23 plan-specific formularies, and expert clinician opinion (from medical oncologists and pharmacists with doctoral-level training practice primarily or exclusively in oncology settings). These look-up tables contain over 2000 NDC and 300 procedure and diagnosis treatment-related codes. Please see Tables 1-3 A297, which contains the lists of codes included in this study. In addition, these tables are accessible through the CRN public website (http://crn.cancer.gov/). Using these chemotherapy-specific and hormone therapy-specific NDC, procedure and diagnosis codes, variables were created and stratified by class of product (chemo vs. hormone therapy). These look-up tables were then mapped to the VDW pharmacy, procedure, and diagnosis files using individual medical record identifiers for all incident breast, colorectal, lung, or prostate cancer cases identified from the VTR (as noted above). If one or more chemotherapy-related or hormone therapy-related event was captured in the VDW files within the first 6 months after the incident diagnosis date then the patient was flagged as receiving therapy at 6 months. Similarly, if a chemotherapyrelated event occurred within the first 12 months after the incident diagnosis date, then the patient was flagged as receiving therapy at 12 months. The first date of a VDWcaptured treatment event in one or more of the VDW files (pharmacy, procedure, or diagnosis) that occurred after the incident cancer diagnosis date noted in the VTR was considered the first chemo or hormone therapy event. The chartabstracted VTR data were extracted from each health plan from the "first course of chemotherapy (or hormone therapy)," variable. If the "first-course chemotherapy" variable was coded as 01, 02, or 03 (chemotherapy, not otherwise specified; chemotherapy, single agent; and chemotherapy, multiple agents), the patient was flagged as having received chemotherapy. Similarly, if the "first-course hormone therapy" was coded as 01 (hormone therapy including not otherwise specified and antihormone), then the patient was flagged as having received hormone therapy treatment.
Data Analysis
For each cancer case, we compared results from the VTR to results from the VDW for chemotherapy and hormone therapy. Because of the small number of cases across all cancers receiving immunotherapy (n = 111), we excluded immunotherapy from this analysis. For 6 and 12 months after cancer diagnosis, we computed sensitivity (proportion of those who were flagged in the VTR as having received treatment and in the VDW as having received treatment), specificity (proportion of those who were flagged in the VTR as NOT receiving treatment and in the VDW as not receiving treatment), and PPV (proportion of those flagged as receiving treatment in the VDW who were correctly identified as receiving treatment by the VTR) by cancer site. We then stratified the data by stage, HMO, and year. Finally, we examined variation in the sensitivity and specificity of the VDW data source (pharmacy vs. procedure and diagnosis files). The pharmacy files capture dispensing of drugs to the infusion unit or outpatient pharmacy, whereas the procedure and diagnosis files capture administration of infusions.
RESULTS
During the 8-year study period, 8543 breast cancer cases, 4399 colorectal cases, 4713 lung cases, and 6145 prostate cancer cases were diagnosed in the participating CRN HMOs. The proportions of breast, colorectal, lung, and prostate cancer cases diagnosed before age 65 were 59%, 37%, 32%, and 42%, respectively. The distributions of incident cancer cases by health plan, cancer site, stage, and year of diagnosis, as well as the proportions of cases indicated by the VTR as receiving chemo or hormone therapy are shown in Table 1 . The majority of breast and prostate cancer cases, in total and by health plan, were initially diagnosed at early stages, whereas colorectal cases were more evenly distributed across all stages. Lung cancers were predominantly diagnosed at later stages. Although not shown here, the distribution of cancer cases by health plan and diagnosis year was relatively stable, with a slight linear increase (from 11.6% in 2000 to 14.2% in 2007) over the observation period. We were unable to link 0.3% (N = 83) of the cancer cases identified in VTR to the VDW files.
Chemotherapy Concordance
Sensitivity across all 3 HMOs was highest for breast (95.5%), followed by colorectal (95.1%,) lung (93%), and prostate cancer (85.5%) ( Table 2) . Specificity for breast, colorectal, lung, and prostate was 89.8%, 92.6%, 92.6%, and 76.6%, respectively. PPVs were generally high ( > 86%), except for prostate cases (6.3%). Sensitivity and specificity varied slightly by health plan with overall measures of concordance the lowest for HMO A. Minimal variation in sensitivity and specificity was noted by stage or year of diagnosis.
When the observation period after diagnosis was extended to 12 months, the sensitivity increased by 0.6 percentage points for colorectal and lung cancer cases and 0.4 percentage points for breast cancer cases (no change was observed for prostate cancer cases). Specificity decreased for breast, colorectal, lung, and prostate cancer cases by 0.4, 2.3, 1.5, and 2.5 percentage points, respectively (data not shown). Table 3 describes the changes in the sensitivity and specificity when the analysis was limited to either only VDW pharmacy NDC data, or only procedures and diagnosis codes associated from outpatient or inpatient encounters derived from the EMRs or claims data. Using pharmacy data only, the largest percentage point decline in sensitivity was found for HMO A across all 4 cancers (34.4-54.6 percentage points), and for prostate cancers at HMO B (42.9 percentage point decline). However, specificity improved from 18.8 to 33.6 percentage points for the same cases. Using only diagnosis and procedure codes, minimal changes were found for HMO A, but large percentage point declines in sensitivity across all 4 cancer sites were found for HMO C, with no improvement in specificity. Moderate declines in the sensitivity (7.8-14 percentage points) were found for breast, colorectal, and lung cases at HMO B.
Hormone Therapy Concordance
Hormone treatment was noted in the VTR data for 4903, 107, 33, and 1706 breast, colorectal, lung, and prostate cancer cases, respectively. Although specificity was high for 
CONCLUSIONS
This is the first evaluation of the consistency between gold standard tumor registry data and automated data derived from the CRN VDW with respect to chemotherapy and hormone therapy use for HMO enrollees aged 18 years or older diagnosed with 1 of the 4 most common cancers in the United States. We found that CRN VDW data associated with coded diagnoses, procedures, and prescription drug use, when used in combination, have both high ( > 90%) sensitivity and specificity for identifying chemotherapy use among breast, colorectal, and lung cancer cases relative to chemotherapy treatment data derived from the chart-abstracted tumor registries. This analysis extends the work by Aiello Bowles et al 24 conducted in these same HMOs, which compared chemotherapy for ovarian cancer patients, based on CPT-4, NDC, and ICD-9-CM codes, to tumor registries and found an overall sensitivity of 89%. Differences found in sensitivity and specificity by HMO and by data source (pharmacy vs. other) could be explained by the differences in source data systems. Two of the 3 HMOs have "in-house" tumor registries employing trained full-time CTRs to conduct comprehensive chart audits, whereas the third populated their VTR from automated SEER data files. The SEER-derived data may be less complete than the "in-house" registries because SEER abstractors do not have continuous access to medical records, which increases the barriers to additional updates beyond the initial chart review. Also consistent with the findings by Aiello Bowles et al, 24 we found that using only 1 source of data (eg, pharmacy only) was insufficient for capturing pharmacologic treatment data. Two of the 3 HMOs had equal capture of pharmacologic events from both the VDW pharmacy and utilization files (capture of both NDC and Healthcare Common Procedure Coding System or CPT-4 codes) for over 90% of the cases receiving chemotherapy, whereas the third captured chemotherapy events predominately from encounter-based diagnoses and procedure files-< 50% of the cases had a chemotherapy-related NDC code. This likely reflects differences in the organization of pharmacy systems within the plan-owned infusion centers.
We found the sensitivity of chemotherapy use capture could be improved only slightly (< 1 percentage point) by extending the observation period from 6 to 12 months, and the same change resulted in reduced specificity (0.4-2.5 percentage points). Differences in sensitivities could be due to delayed start of therapy for reasons related to other cancer care (eg, surgery, radiation), whereas the drop in specificity may be associated with recurrence or progression. 25 Conversely, the sensitivity estimate for hormone therapy for breast cancer cases improved by almost 20 percentage points (72.3%-92.2%) when the observation period was extended to 12 months. This is not surprising given that hormone therapy often is not started until after adjuvant chemotherapy treatment is complete, and suggests that future research related to hormone therapy that uses CRN VDW data should consider using a 12-month observation period.
In evaluating the PPV results, it is important to note that the VTR is limited to first-treatment course, a restriction that cannot be applied to the coded diagnoses, procedures, and prescription drug use VDW data. The chemotherapy PPV for prostate cancer cases was low, but the hormone therapy PPV was high ( > 90% overall). Chemotherapy is frequently only initiated in prostate cancer for advanced disease or with progression or recurrence 26, 27 ; consistent with this, only 1.8% of cases (n = 111) in the VTR received primary chemotherapy treatment, whereas 27% of cases within the VDW pharmacy or procedure data received chemotherapy within 12 months of the diagnosis date. The hormone therapy PPV values are consistent with use of a variety of treatment approaches that can be initiated at various times after diagnosis. 28 There are several limitations associated with this study. We did not conduct chart reviews of false-negative cases (indicated as having treatments from VTR data, but no VDW pharmacy, procedure, or diagnosis-related event). At least some of these cases likely reflect 3%-5% of cancer patients (enrolled in these HMOs) who are participating in chemotherapy-related clinical trials. The health plan is not liable for the cost of the chemotherapy, nor is the trial drug necessarily part of the health plan's pharmacy formulary. Therefore, if the trial drug was administered at a cancer center or by another contract provider, it would be noted in the chart-abstracted tumor registry, but no claim would be generated. If the trial drug was administered by the plan-owned infusion center, the trial drug may not be captured or included in the traditional pharmacy systems. In addition, the 2 health plans with internal tumor registries (non-SEER) generally perform chart abstraction in most cases within 6-8 months of the cancer diagnosis date. However, the CTRs at these plans have continuous access to the patient's EMR, allowing for abstraction updates in cases when first-course treatment may be delayed by several months. This may result in a longer follow-up abstraction period relative to SEER registries. The potential for differences in SEER/non-SEER abstraction follow-up could also be the source of variation in specificities across health plans. Further, although we assumed that the first chemotherapy event after the diagnosis date of 1 of the 4 cancers of interest corresponded to that cancer, we did not limit cases to sequence 0 (first incident cancer). It is therefore possible that we are identifying cancer treatments associated with a previous cancer diagnoses. Future studies should also explore product, or regimen-level specificities, sensitivities, and PPVs, consistent with Warren et al, 4 particularly as standardized electronic infusion therapy record systems are deployed across the majority of the CRN HMOs, further improving the quality and clarity of antineoplastic data.
Regardless of future data refinements, the results of the current multisite analysis reveal that CRN VDW-based cancer treatment data are as sensitive and specific as Medicare fee-for-service claims data in identifying receipt of antineoplastic therapy-the dominant data source used for research related to cancer treatment and outcomes. 4, 6, 29 Furthermore, this study highlights the ability of the CRN VDW to capture hormonal and oral chemotherapeutics at a time when Medicare part D pharmacy data are not currently available through linked SEER-Medicare files. Finally, our study is one of a limited few that includes a representative population of cancer patients under the age of 65 years. This unique, comprehensive, and reliable data source sets the stage for patterns of care analyses and comparative effectiveness research in community-based oncology settings that will inform policy and medical practice by enabling better understanding of similarities and differences in cancer epidemiology, treatment patterns, and outcomes between aged and nonaged populations and between capitated and fee-for-service reimbursement systems.
